Useful and potentially useful urine markers for bladder cancer. | Download Table
Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non–muscle-invasive bladder cancer and with low and intermediate EORTC-risk score | PLOS ONE
Cancers | Free Full-Text | Noninvasive Urine-Based Tests to Diagnose or Detect Recurrence of Bladder Cancer
Cepheid | Bladder Cancer Monitor Biomarker Test - Xpert Bladder Cancer Monitor
Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study - eBioMedicine
Artificial intelligence: A promising frontier in bladder cancer diagnosis and outcome prediction - ScienceDirect
Unmet Clinical Needs and Future Perspectives in Non–muscle-invasive Bladder Cancer - European Urology Focus
Bladder Cancer Survival: The Importance of Early Detection | Cxbladder
Urinary biomarkers to mitigate diagnostic delay in bladder cancer during the COVID-19 era | Nature Reviews Urology
Summary of urinary markers for bladder cancer | Download Table
Bladder Cancer Markers and Recent Innovations | IntechOpen
Frontiers | Urinary Markers in Bladder Cancer: An Update
Non muscle invasive bladder cancer treatment - WCRJ
Recurrent ZNF83-E293V Mutation Promotes Bladder Cancer Progression through the NF-κB Pathway via Transcriptional Dysregulation of S100A8: Molecular Therapy
This policy documents the coverage determination for Urinary Tumor Markers for Bladder Cancer. The diagnosis of bladder cancer i
JCI - Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer
Dr. Peter Black | Urine Markers for Bladder Cancer | The Ideal Marker
Bladder Cancer Biomarkers | Encyclopedia MDPI
Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight - ScienceDirect
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study - The Lancet Oncology
Urinary peptide panel for prognostic assessment of bladder cancer relapse | Scientific Reports
FEP 2.04.07 Urinary Biomarkers for Cancer Screening, Diagnosis, and Surveillance
